CalciMedica (CALC) Non Operating Interest Expenses (2025 - 2026)
CalciMedica's (CALC) quarterly Non Operating Interest Expenses came in at $325000.0 in Q2 2026, little changed on a YoY basis from $324000.0 in Q2 2025, and up 1.88% quarter-over-quarter from $319000.0 in Q1 2026.
Powered by 
Analysis
CalciMedica (CALC) Non Operating Interest Expenses (2025 - 2026) Analysis & Trends
CalciMedica (CALC) has reported Non Operating Interest Expenses for 2 consecutive years, with $325000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non Operating Interest Expenses changed 0.31% year-over-year to $325000.0; the trailing twelve-month figure through Jun 2026 stood at $1.3 million (up 67.96% YoY), and the FY2025 full-year result was $1.4 million, changed N/A from the prior year.
- Non Operating Interest Expenses climbed to $325000.0 in Q2 2026 per CALC's latest filing, from $319000.0 in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at $447000.0 in Q1 2025 and bottomed at $319000.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -462.00 Mn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -333.60 Mn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 23.78 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 582,000.00 |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 2.90 Mn |
| 10 | CalciMedica | 7.90 Mn | -10.72 Mn | - | 325,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 325,000.00 |
| Mar 31, 2026 | 319,000.00 |
| Dec 31, 2025 | 325,000.00 |
| Sep 30, 2025 | 326,000.00 |
| Jun 30, 2025 | 324,000.00 |
| Mar 31, 2025 | 447,000.00 |